產(chǎn)品中心Cell Resources
聯(lián)系我們CONTACT US
- 400-999-210024小時(shí)服務(wù)熱線
產(chǎn)品概述
名稱 | NCI-H292 (人肺癌細(xì)胞(淋巴結(jié)轉(zhuǎn)移)) (STR鑒定正確) |
別稱 | H292; H-292; NCI-HUT-292; Hut292; NCIH292 |
種屬 | 人 |
生長(zhǎng)特性 | 貼壁細(xì)胞 |
細(xì)胞形態(tài) | 上皮細(xì)胞樣 |
凍存條件 | 凍存液:55% 基礎(chǔ)培養(yǎng)基+40%FBS+5%DMSO 溫度:液氮 |
培養(yǎng)方案A(默認(rèn)) |
培養(yǎng)條件:
氣相:空氣,95%;CO2,5%, 溫度:37℃
|
推薦傳代比例 | 1:3-1:4 |
推薦換液頻率 | 2-3次/周 |
背景描述 | NCI-H292細(xì)胞源自肺支氣管黏液上皮樣癌的淋巴結(jié)轉(zhuǎn)移灶;先用成份限定的培養(yǎng)基分離得到,然后換成含血清的培養(yǎng)基培養(yǎng)。培養(yǎng)條件下,NCI-H292細(xì)胞保留了黏液上皮的特性,可從其超微結(jié)構(gòu)的表現(xiàn)和多種鱗狀上皮分化標(biāo)記的表達(dá)而判斷。NCI-H292細(xì)胞支持HBV的生長(zhǎng),左旋多巴脫羧酶陰性。NCI-H292細(xì)胞可以作為篩選模型,將人類亞基因組片段轉(zhuǎn)染入細(xì)胞來研究HBV及其自身基因在病毒性肝炎和肝癌發(fā)生中的作用。NCI-H292細(xì)胞角蛋白、波形蛋白、黏液洋紅染色陽線,但神經(jīng)絲三聯(lián)蛋白陰性。 |
年齡(性別) | 女性;32歲 |
組織來源 | 肺粘膜上皮細(xì)胞癌;肺 |
細(xì)胞類型 | 腫瘤細(xì)胞 |
腫瘤類型 | 肺癌細(xì)胞 |
生物安全等級(jí) | BSL-1 |
倍增時(shí)間 | ~48 hours |
致瘤性 | Yes, in nude mice; tumors histologically resemble the original biopsy specimen and retain mucoepidermoid features. |
基因表達(dá)情況 | keratin; vimentin,The cells retain their mucoepidermoid characteristics in culture as determined by their ultrastructure and expression of multiple markers of squamous differentiation. TANK cells show reactivity with human alloantisera specific for the HLA A1, A3, A10, A19, B12, B17, B22 and B40 cross-reactive groups. |
保藏機(jī)構(gòu) | ATCC; CRL-1848 |
STR鑒定
-
STR位點(diǎn)信息
Amelogenin X CSF1PO 10 D2S1338 21,24 D3S1358 16 D5S818 13 D7S820 10 D8S1179 11,14 D13S317 11,12 D16S539 9,13 D18S51 16 D19S433 12,13.2 D21S11 28 FGA 22,26 PentaD 9 PentaE 13,15 TH01 8 TPOX 8,11 vWA 16,17 D6S1043 11,12 D12S391 16,20 D2S441 11,12 -
STR鑒定圖
參考文獻(xiàn)
-
LINC00173.v1 Promotes Angiogenesis and Progression of Lung Squamous Cell Carcinoma by Sponging miR-511-5p to Regulate VEGFA Expression(2020/07/10)
作者:Aibin Liu
期刊:Molecular Cancer
DOI:10.1186/s12943-020-01217-2
影響因子 :37.300
-
Lnc AC016727.1/BACH1/HIF-1 α signal loop promotes the progression of non-small cell lung cancer(2023/11/10)
作者:Li Zhang, Jingtian Liang, Hao Qin
期刊:JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
DOI:10.1186/s13046-023-02875-y
影響因子 :11.300
引用產(chǎn)品:CL-0167
-
Therapeutic potential of Lianhua Qingke in airway mucus hypersecretion of acute exacerbation of chronic obstructive pulmonary disease(2023/11/03)
作者:Yuanjie Hao, Tongxing Wang, Yunlong Hou
期刊:Chinese Medicine
DOI:10.1186/s13020-023-00851-4
影響因子 :4.900
引用產(chǎn)品:CL-0167
-
Soy isoflavone genistein inhibits hsa_circ_0031250/miR‐873‐5p/FOXM1 axis to suppress non‐small‐cell lung cancer progression(2020/11/7)
作者:Yaying Yu, Yanwei Xing, Qian Zhang
期刊:Iubmb Life
DOI:10.1002/iub.2404
影響因子 :4.600
引用產(chǎn)品:CL-0167
-
Tanshinone IIA (TSIIA) represses the progression of non-small cell lung cancer by the circ_0020123/miR-1299/HMGB3 pathway(2022/12/31)
作者:Fei Sun, Xiaoli Yang, Wei Song
期刊:MOLECULAR AND CELLULAR BIOCHEMISTRY
DOI:10.1007/s11010-022-04646-3
影響因子 :4.300
引用產(chǎn)品:164210 164210-50 CL-0016 CL-0167 PB180120 PM150110 PM150910
-
circPDK1 competitively binds miR-4731-5p to mediate GIGYF1 expression and increase paclitaxel sensitivity in non-small cell lung cancer(2024/05/11)
作者:YunYin Feng, TaoLong Zhang, Hong Liu
期刊:Discover Oncology
DOI:10.1007/s12672-024-01003-2
影響因子 :2.200
引用產(chǎn)品:CL-0167
FAQs
Q:{{item.question}}
A:
產(chǎn)品資料
識(shí)別碼示意圖